Holen Sie sich die Stockscreener-App
12.40
1.12%
-0.14
Handel nachbörslich:
12.30
-0.10
-0.81%
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Why (ZVRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Zevra Therapeutics to Present at Upcoming Investor Conferences - Yahoo Finance
Zevra Therapeutics Presents Long-Term Real-World Data Supporting MIPLYFFA in Niemann-Pick Disease Type C at SSIEM Annual Symposium - Quiver Quantitative
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium - Barchart.com
A rare-disease drug has up to 8 years of real-world data. Zevra will present the findings. - Stock Titan
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Four new Zevra employees receive stock options that vest over four years - Stock Titan
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $26 - Moomoo
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today? - Stocktwits
H.C. Wainwright reiterates Zevra Therapeutics stock rating at buy - Investing.com
Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright reiterates Zevra Therapeutics stock rating at buy By Investing.com - Investing.com Canada
ZVRA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $26 - GuruFocus
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics Insider Sold Shares Worth $474,774, According to a Recent SEC Filing - marketscreener.com
Zevra Therapeutics (ZVRA) insider sells 42,666 shares - Stock Titan
Price-Driven Insight from (ZVRA) for Rule-Based Strategy - Stock Traders Daily
Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker - Stock Titan
Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position - Stock Titan
ZVRA Q2 2026 Earnings: EPS Beats Estimates by 27.85% as Bottom-Line Strength ContinuesLow Estimate Range - vinanet.vn
Price to earnings forward of Zevra Therapeutics, Inc. – FWB:1GDA - TradingView
Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc.ZVRA - PR Newswire
Canaccord Genuity Sticks to Its Buy Rating for Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock - MarketBeat
Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics at Canaccord Genuity: growth plan widens By Investing.com - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therape - The National Law Review
Hennion & Walsh Asset Management Inc. Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
HC Wainwright Has Positive Outlook for ZVRA FY2027 Earnings - marketbeat.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Reach Out - ACCESS Newswire
Why Zevra Therapeutics (ZVRA) Is Up 21.6% After Strong MIPLYFFA Uptake And New Real-World Data - Sahm
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zevra Therapeutics, Inc. (ZVRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Zevra Therapeutics, Inc. (ZVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
ZVRA Maintained by Guggenheim -- Price Target Lowered to $23.00 - GuruFocus
Zevra Therapeutics (NASDAQ:ZVRA) Price Target Lowered to $23.00 at Guggenheim - MarketBeat
FY2026 EPS Forecast for Zevra Therapeutics Raised by Analyst - MarketBeat
Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: A Biotech Stock with 113% Potential Upside - DirectorsTalk Interviews
What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review? - Yahoo Finance
ZVRA Maintained by Citizens -- Price Target Raised to $28.00 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Investors to Connect - ACCESS Newswire
Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 14.1% on Better-Than-Expected Earnings - MarketBeat
Zevra Therapeutics (ZVRA) gains FMR LLC and Abigail Johnson 8.3% stake disclosure - Stock Titan
Zevra Therapeutics, Inc. Stock 12‑Month Price Target Raised to $25.11, Implies 138% Upside - TradingView
Zevra Therapeutics Q2 Earnings Call Highlights - MarketBeat
Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights - GuruFocus
Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights: Revenue Surges 53% as ... - Yahoo Finance
ZVRA Looks 54.4% Undervalued on GF Value™ at $10.54 - GuruFocus
Earnings call transcript: Zevra beats Q2 2026 estimates as MIPLYFFA sales rise - Investing.com
ZVRA Looks 54.4% Undervalued on GF Value™ as Market Weighs Q2 Re - GuruFocus
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Is Zevra Therapeutics Inc (ZVRA) Underperforming After Q2 2026 E - GuruFocus
Zevra Therapeutics (NASDAQ:ZVRA) Announces Quarterly Earnings Results - MarketBeat
Zevra Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Zevra Therapeutics (ZVRA) Releases Q2 2026 Earnings: Revenue Growth and EPS Beat - Quiver Quantitative
ZEVRA THERAPEUTICS, INC. 2026: Revenue $39.66M, EPS $0.14— 10-Q Summary - TradingView
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) posts Q2 profit, repays debt - Stock Titan
Zevra Therapeutics: Q2 Earnings Snapshot - marketscreener.com
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):